To the Editor As authors of articles cited by Louis and Lampiris,1 we have a different view of the evidence that should inform recommendations about treating influenza with neuraminidase inhibitors.
Louis and Lampiris1 champion conclusions from observational studies. They judged the evidence from randomized clinical trials as inadequate because such trials have not been carried out in high-risk populations, which they defined as including children and the elderly. However, we analyzed 13 such placebo-controlled randomized clinical trials in our Cochrane review.2
Doshi P, Jefferson T. Neuraminidase Inhibitors and Influenza Infection. JAMA Intern Med. 2016;176(3):415-416. doi:10.1001/jamainternmed.2016.0016